GlassScriptPhysician profile
Mary C Newman
NPI 1417049040
$369.89
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $64.56 · 2021: $77.88 · 2022: $38.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.61 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.75 | 2021-2022 | |
| Radius Health, INC. | $27.43 | 2019 | |
| Lilly USA, LLC | $20.03 | 2021 | |
| Medtronic Minimed, INC. | $19.25 | 2019 | |
| Recordati_rare_diseases_inc. | $18.69 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $18.55 | 2020 | |
| Chiasma, INC. | $12.86 | 2021 | |
| Genentech USA, INC. | $12.72 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.